World Health Organization Sounds Alert Over Severe Lack of Weight-Loss Jabs
Under one in 10 patients eligible to benefit from GLP-1 drugs such as Wegovy can access them, caution the World Health Organization as it releases its inaugural recommendations on the therapies.
With more than one billion individuals worldwide currently obese, it is advocating for broader and more equitable availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The latest guidelines affirms that excess weight is a chronic disease that can be managed with thorough and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to broad access to the jabs that can help people shift substantial weight, says the organization.
GLP-1 Therapy Supply Crisis
Despite the current best projected outlook, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of those who need them, according to the WHO.
The guideline urges countries and companies to widen availability, by strategies like patent sharing.
The intellectual property rights on semaglutide – the main component of the drug Wegovy – is due to expire in a number of countries in 2026.
The Way Obesity Injections Function
These medications mimick a biological compound to reduce digestion speed, reduce hunger and enhance satiety so individuals consume fewer calories.
People commonly see weight reduction after several weeks of commencing the weekly injections.
Evidence indicates people may put most of the weight back on within a year of halting the drug, because their usual hunger return.
To be overweight or obese elevates your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
